Siemens Healthineers AGMEX:SHL N 72 Net Margin % is 8.91% as of Mar. 2026, which is 6% below its 10-year median of 9.51. GuruFocus rates MEX:SHL N with a GF Score™ of 72/100 and a GF Value™ of MXN1,405.64. The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Siemens Healthineers AG ranks better than 70.87% on this metric.
The historical rank and industry rank for Siemens Healthineers AG's Net Margin % or its related term are showing as below:
MEX:SHL N'
s Net Margin % Range Over the Past 10 Years
Min: 6.96 Med: 9.51 Max: 10.79
Current: 9.08
MEX:SHL N's Net Margin % is ranked better than 70.87% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs MEX:SHL N: 9.08
Siemens Healthineers AG (MEX:SHL N) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Siemens Healthineers AG Net Margin % Related Terms
Siemens Healthineers AG Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SHL N vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Siemens Healthineers AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Siemens Healthineers AG Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Siemens Healthineers AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where Siemens Healthineers AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Siemens Healthineers AG (MEX:SHL N) has a Net Margin % of 8.91% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Siemens Healthineers AG and its competitors. This is near median its historical median of 9.51. Over the past decade, Siemens Healthineers AG's Net Margin % has ranged from 6.96 to 10.79. According to the industry distribution chart, Siemens Healthineers AG ranks #238 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 29.1%.
Is Siemens Healthineers AG's Net Margin % too high?
Siemens Healthineers AG's current Net Margin % of 8.91% is near median its 10-year median of 9.51. Over the past 10 years, this metric has ranged from a low of 6.96 to a high of 10.79. The Medical Devices & Instruments industry median Net Margin % is 2.07. Siemens Healthineers AG's value of 8.91% is 330.4% above this industry median. Based on the distribution chart, Siemens Healthineers AG ranks #238 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Siemens Healthineers AG has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Siemens Healthineers AG's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Siemens Healthineers AG ranks #238 out of 817 companies for Net Margin %. This puts Siemens Healthineers AG in the upper half of its industry. The industry median Net Margin % is 2.07. Siemens Healthineers AG's value of 8.91% is 330.4% above this benchmark. Historically, Siemens Healthineers AG's own Net Margin % has ranged from 6.96 to 10.79 over the past decade. While the company's 10-year median is 9.51 vs. the industry median of 2.07, Siemens Healthineers AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Siemens Healthineers AG's current Net Margin % of 8.91% is 330.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Siemens Healthineers AG and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Siemens Healthineers AG's current Net Margin % is 8.91%, which is near median its own 10-year median of 9.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Siemens Healthineers AG stock overvalued right now?
Siemens Healthineers AG (MEX:SHL N) has a current Net Margin % of 8.91%. The stock's GF Value™ is MXN1,405.64, compared to a current price of MXN918.93 — trading 34.6% below its estimated fair value. The current Net Margin % is 8.91%, which is near median its 10-year median of 9.51 and 330.4% above the Medical Devices & Instruments industry median of 2.07. Siemens Healthineers AG's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Siemens Healthineers AG (MEX:SHL N), the current Net Margin % is 8.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Siemens Healthineers AG (MEX:SHL N) Overvalued in 2026?
Based on GuruFocus' analysis, Siemens Healthineers AG stock appears to be undervalued.
The current stock price of MXN918.93 is trading 34.6% below its estimated GF Value™ of MXN1,405.64.
Key valuation signals for MEX:SHL N:
Net Margin %: 8.91% (near median its 10-year median of 9.51)
GF Value™: MXN1,405.64 vs. price of MXN918.93 (34.6% below fair value)
Industry Position: 330.4% above the Medical Devices & Instruments median (#238 of 817)
No single metric tells the full story. See the MEX:SHL N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (56% of sales in fiscal 2025) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (18% of sales) offers radiotherapy and other oncology solutions. The diagnostics segment (19%) includes in vitro diagnostics and point-of-care diagnostics. The advanced therapies (now part of precision therapy) segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. The Americas represents 44% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific, including China (11%), the remainder.
72GF Score
Get the complete analysis for MEX:SHL N
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SHL N has been successfully added to your 
